Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Riverfolkon Aug 12, 2021 9:26am
77 Views
Post# 33690875

House Positions since recent upswing

House Positions since recent upswing
House Positions for C:ARCH from 20210716 to 20210812
House Bought $Val Ave Sold $Val Ave Net $Net
22 Fidelity 355,300 495,932 1.396 15,000 22,200 1.48 340,300 -473,732
83 Mackie 120,000 155,600 1.297 0   120,000 -155,600
79 CIBC 65,153 90,029 1.382 24,433 34,379 1.407 40,720 -55,650
85 Scotia 44,549 63,125 1.417 11,564 15,276 1.321 32,985 -47,849
89 Raymond James 30,251 42,139 1.393 3,814 4,843 1.27 26,437 -37,296
9 BMO Nesbitt 85,750 117,435 1.37 69,000 96,398 1.397 16,750 -21,037
2 RBC 42,539 60,246 1.416 27,415 38,861 1.418 15,124 -21,385
124 Questrade 15,204 19,963 1.313 4,500 6,476 1.439 10,704 -13,487
39 Merrill Lynch 5,500 7,815 1.421 0   5,500 -7,815
80 National Bank 7,437 9,607 1.292 3,883 5,668 1.46 3,554 -3,939
88 Credential 0   100 145 1.45 -100 145
13 Instinet 0   720 1,056 1.467 -720 1,056
57 Interactive 0   1,200 1,826 1.522 -1,200 1,826
68 Leede 709 998 1.408 5,880 8,626 1.467 -5,171 7,628
33 Canaccord 3,028 4,360 1.44 12,060 17,681 1.466 -9,032 13,321
62 Haywood 0   15,000 19,800 1.32 -15,000 19,800
14 ITG 14,830 21,146 1.426 39,400 53,352 1.354 -24,570 32,206
143 Pershing 0   28,900 40,350 1.396 -28,900 40,350
53 Morgan Stanley 0   85,000 115,244 1.356 -85,000 115,244
7 TD Sec 51,419 71,721 1.395 146,537 201,829 1.377 -95,118 130,108
1 Anonymous 163,724 227,944 1.392 510,987 704,053 1.378 -347,263 476,109
TOTAL 1,005,393 1,388,060 1.381 1,005,393 1,388,063 1.381 0 3

<< Previous
Bullboard Posts
Next >>